Medscape
The US Food and Drug Administration (FDA) has approved ustekinumab-srlf (Imuldosa) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the fifth ustekinumab biosimilar approved by the FDA, and it is expected to become available in the first half of 2025. …
Read More
FDA Approves Fifth Ustekinumab Biosimilar
Erasmo Mischke
20:56
The US Food and Drug Administration (FDA) has approved ustekinumab-srlf (Imuldosa) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the fifth ustekinumab biosimilar approved by the FDA, and it is expected to become available in the first half of 2025. …
